Managing a strategic industry-academia alliance for drug discovery: a case study of the Astellas Pharma Inc.-Kyoto University Project Online publication date: Fri, 21-Nov-2014
by Chikako Saotome; Seiji Abe; Yutaka Teranishi; Shuh Narumiya
International Journal of Technology Transfer and Commercialisation (IJTTC), Vol. 11, No. 3/4, 2012
Abstract: Pharmaceutical companies are now facing a so-called 'patent-cliff', suffer from decreased profits and are conducting various trials of open innovation, which deviates from their autarkic R&D model. Academia is also suffering from financial cut-backs in governmental support for general activity and research. To overcome these two current problems, it is essential to create a new model of industry-academia cooperation. The Astellas Pharma Inc.-Kyoto University Project (AK Project), which started in 2007, is a strategic alliance for the development of immunotherapeutics. It also serves as an open innovation model whose primary purpose is to revitalise both industry and academia. This paper describes how to manage the collaboration to simultaneously accelerate science and drug development and how to synergise efforts between academia and industry by shuttling between the bench and the bed-side. This paper also discusses how to manage intellectual property, especially with respect to the coordination of patent applications and publications.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Transfer and Commercialisation (IJTTC):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com